PARP inhibitors in the treatment of Pancreatic Cancer - A Review of literature
Introduction Pancreatic cancer is one of the most aggressive cancers. It occurs in men more often than women. The primary therapy for these cancers is surgery; chemotherapy, radiation therapy, hormone therapy, or immunotherapy are also used. More and better treatments are being sought for this...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kazimierz Wielki University
2025-01-01
|
| Series: | Journal of Education, Health and Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/JEHS/article/view/56992 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590732470255616 |
|---|---|
| author | Jagoda Niewiadomska Wiktor Grela Daria Furtak Dawid Tulej Paulina Głogowska Alicja Dziedzic Natalia Gniaź Dominika Marciniuk Natalia Marko Aleksandra Górska |
| author_facet | Jagoda Niewiadomska Wiktor Grela Daria Furtak Dawid Tulej Paulina Głogowska Alicja Dziedzic Natalia Gniaź Dominika Marciniuk Natalia Marko Aleksandra Górska |
| author_sort | Jagoda Niewiadomska |
| collection | DOAJ |
| description |
Introduction
Pancreatic cancer is one of the most aggressive cancers. It occurs in men more often than women. The primary therapy for these cancers is surgery; chemotherapy, radiation therapy, hormone therapy, or immunotherapy are also used. More and better treatments are being sought for this disease. The use of PARP inhibitors in the treatment of pancreatic cancer has shown good results, so in this article we have done a review of the results of various studies on this topic. In this review, the results of studies on the use of various PARP inhibitors in pancreatic cancer of different hormonal status are presented.
Purpose
This article aims to give you an overview of the trials that have looked at the effects of different PARP inhibitors in the treatment of pancreatic cancer. PARP inhibitors are a relatively new cancer therapy with good results, so it is important to pay attention.
State of Knowledge
In this article, I used the PubMed database and considered papers from the last 10 years, but most of the information in this review comes from papers published after 2020. I have also taken into account the recommendations of the FDA and the European Medicines Agency on the use of PARP inhibitors.
Conclusions
PARP inhibitors have shown significant effects on pancreatic cancer outcomes. The differences in outcomes depending on the type of cancer, the PARP inhibitor used, and the previous therapies used in a given patient tell us how important it is to individualize therapy in oncology. The findings of the studies presented in this review also point to the need for further research that could focus on identifying patients who may best benefit from treatment with PARP inhibitors, as well as studying synergistic effects in combination with other forms of therapy, such as immunotherapy or chemotherapy. The changes in treatment outcomes that these drugs can bring underscore the importance of exploring new therapeutic strategies in oncology.
|
| format | Article |
| id | doaj-art-2ea1c061429244f69c97e34a11889e3a |
| institution | Kabale University |
| issn | 2391-8306 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Kazimierz Wielki University |
| record_format | Article |
| series | Journal of Education, Health and Sport |
| spelling | doaj-art-2ea1c061429244f69c97e34a11889e3a2025-01-23T08:17:27ZengKazimierz Wielki UniversityJournal of Education, Health and Sport2391-83062025-01-017710.12775/JEHS.2025.77.56992PARP inhibitors in the treatment of Pancreatic Cancer - A Review of literatureJagoda Niewiadomska0https://orcid.org/0009-0003-2219-984XWiktor Grelahttps://orcid.org/0009-0000-5801-5756Daria Furtakhttps://orcid.org/0000-0003-0768-9800Dawid Tulejhttps://orcid.org/0000-0002-5711-3423Paulina Głogowskahttps://orcid.org/0009-0002-3003-4466Alicja Dziedzichttps://orcid.org/0009-0001-0460-4106Natalia Gniaźhttps://orcid.org/0009-0008-3329-9770Dominika Marciniukhttps://orcid.org/0009-0000-0710-8485Natalia Markohttps://orcid.org/0009-0004-7815-4592Aleksandra Górskahttps://orcid.org/0009-0004-0141-2821Uniwersytet Medyczny w Lublinie Introduction Pancreatic cancer is one of the most aggressive cancers. It occurs in men more often than women. The primary therapy for these cancers is surgery; chemotherapy, radiation therapy, hormone therapy, or immunotherapy are also used. More and better treatments are being sought for this disease. The use of PARP inhibitors in the treatment of pancreatic cancer has shown good results, so in this article we have done a review of the results of various studies on this topic. In this review, the results of studies on the use of various PARP inhibitors in pancreatic cancer of different hormonal status are presented. Purpose This article aims to give you an overview of the trials that have looked at the effects of different PARP inhibitors in the treatment of pancreatic cancer. PARP inhibitors are a relatively new cancer therapy with good results, so it is important to pay attention. State of Knowledge In this article, I used the PubMed database and considered papers from the last 10 years, but most of the information in this review comes from papers published after 2020. I have also taken into account the recommendations of the FDA and the European Medicines Agency on the use of PARP inhibitors. Conclusions PARP inhibitors have shown significant effects on pancreatic cancer outcomes. The differences in outcomes depending on the type of cancer, the PARP inhibitor used, and the previous therapies used in a given patient tell us how important it is to individualize therapy in oncology. The findings of the studies presented in this review also point to the need for further research that could focus on identifying patients who may best benefit from treatment with PARP inhibitors, as well as studying synergistic effects in combination with other forms of therapy, such as immunotherapy or chemotherapy. The changes in treatment outcomes that these drugs can bring underscore the importance of exploring new therapeutic strategies in oncology. https://apcz.umk.pl/JEHS/article/view/56992PARP inhibitorspancreatic cancercancer treatment |
| spellingShingle | Jagoda Niewiadomska Wiktor Grela Daria Furtak Dawid Tulej Paulina Głogowska Alicja Dziedzic Natalia Gniaź Dominika Marciniuk Natalia Marko Aleksandra Górska PARP inhibitors in the treatment of Pancreatic Cancer - A Review of literature Journal of Education, Health and Sport PARP inhibitors pancreatic cancer cancer treatment |
| title | PARP inhibitors in the treatment of Pancreatic Cancer - A Review of literature |
| title_full | PARP inhibitors in the treatment of Pancreatic Cancer - A Review of literature |
| title_fullStr | PARP inhibitors in the treatment of Pancreatic Cancer - A Review of literature |
| title_full_unstemmed | PARP inhibitors in the treatment of Pancreatic Cancer - A Review of literature |
| title_short | PARP inhibitors in the treatment of Pancreatic Cancer - A Review of literature |
| title_sort | parp inhibitors in the treatment of pancreatic cancer a review of literature |
| topic | PARP inhibitors pancreatic cancer cancer treatment |
| url | https://apcz.umk.pl/JEHS/article/view/56992 |
| work_keys_str_mv | AT jagodaniewiadomska parpinhibitorsinthetreatmentofpancreaticcancerareviewofliterature AT wiktorgrela parpinhibitorsinthetreatmentofpancreaticcancerareviewofliterature AT dariafurtak parpinhibitorsinthetreatmentofpancreaticcancerareviewofliterature AT dawidtulej parpinhibitorsinthetreatmentofpancreaticcancerareviewofliterature AT paulinagłogowska parpinhibitorsinthetreatmentofpancreaticcancerareviewofliterature AT alicjadziedzic parpinhibitorsinthetreatmentofpancreaticcancerareviewofliterature AT nataliagniaz parpinhibitorsinthetreatmentofpancreaticcancerareviewofliterature AT dominikamarciniuk parpinhibitorsinthetreatmentofpancreaticcancerareviewofliterature AT nataliamarko parpinhibitorsinthetreatmentofpancreaticcancerareviewofliterature AT aleksandragorska parpinhibitorsinthetreatmentofpancreaticcancerareviewofliterature |